Exportar registro bibliográfico


Metrics:

Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles (2018)

  • Authors:
  • Autor USP: WRENGER, CARSTEN - ICB
  • Unidade: ICB
  • DOI: 10.1007/s00204-018-2165-4
  • Subjects: PARASITOLOGIA; ANTAGONISMO DE DROGAS; CÉLULAS KUPFFER
  • Agências de fomento:
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso à fonteDOI
    Informações sobre o DOI: 10.1007/s00204-018-2165-4 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      BURK, Oliver; KUZIKOV, Maria; KRONENBERGER, Thales; et al. Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Archives of Toxicology, Heidelberg, Springer, v. 92, p. 1435-1451, 2018. Disponível em: < https://doi.org/10.1007/s00204-018-2165-4 > DOI: 10.1007/s00204-018-2165-4.
    • APA

      Burk, O., Kuzikov, M., Kronenberger, T., Jeske, J., Keminer, O., Thasler, W.  E.  , et al. (2018). Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Archives of Toxicology, 92, 1435-1451. doi:10.1007/s00204-018-2165-4
    • NLM

      Burk O, Kuzikov M, Kronenberger T, Jeske J, Keminer O, Thasler W E , Schwab M, Wrenger C, Windshügel B. Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles [Internet]. Archives of Toxicology. 2018 ; 92 1435-1451.Available from: https://doi.org/10.1007/s00204-018-2165-4
    • Vancouver

      Burk O, Kuzikov M, Kronenberger T, Jeske J, Keminer O, Thasler W E , Schwab M, Wrenger C, Windshügel B. Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles [Internet]. Archives of Toxicology. 2018 ; 92 1435-1451.Available from: https://doi.org/10.1007/s00204-018-2165-4

    Referências citadas na obra
    Arnold KA, Eichelbaum M, Burk O (2004) Alternative splicing affects the function and tissue-specific expression of the human constitutive androstane receptor. Nucl Recept 2:1. https://doi.org/10.1186/1478-1336-2-1
    Bitter A, Rümmele P, Klein K et al (2015) Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Arch Toxicol 89:2089–2103. https://doi.org/10.1007/s00204-014-1348-x
    Boulin M, Guiu S, Chauffert B et al (2011) Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs 22:741–748. https://doi.org/10.1097/CAD.0b013e328346a0c5
    Bros M, Ross X-L, Pautz A et al (2003) The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer. J Immunol 171:1825–1834. https://doi.org/10.4049/jimmunol.171.4.1825
    Burk O, Tegude H, Koch I et al (2002) Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277:2428–24288. https://doi.org/10.1074/jbc.M202345200
    Burk O, Arnold KA, Nussler AK et al (2005) Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 67:1954–1965. https://doi.org/10.1124/mol.104.009019
    Chai SC, Cherian MT, Wang Y-M, Chen T (2016) Small-molecule modulators of PXR and CAR. Biochim Biophys Acta 1859:1141–1154. https://doi.org/10.1016/j.bbagrm.2016.02.013
    Chen T (2010) Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev 62:1257–1264. https://doi.org/10.1016/j.addr.2010.07.008
    Chen Y, Tang Y, Robbins GT, Nie D (2010) Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J Pharmacol Exp Ther 334:999–1008. https://doi.org/10.1124/jpet.110.168294
    Chen Y, Tang Y, Guo C et al (2012) Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 83:1112–1226. https://doi.org/10.1016/j.bcp.2012.01.030
    Chrencik JE, Orans J, Moore LB et al (2005) Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol 19:1125–1134. https://doi.org/10.1210/me.2004-0346
    Das B, Madhukumar A, Anguiano J et al (2008) Synthesis of novel ketoconazole derivatives as inhibitors of the human pregnane X receptor (PXR; NR1I2; also termed SXR, PAR). Bioorg Med Chem Lett 15:3974–3977. https://doi.org/10.1016/j.bmcl.2008.06.018
    Deng Y, Sychterz C, Suttle AB et al (2013) Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica 43:443–453. https://doi.org/10.3109/00498254.2012.734642
    Ekins S, Kholodovych V, Ai N et al (2008) Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol 74:662–672. https://doi.org/10.1124/mol.108.049437
    Elentner A, Ortner D, Clausen B et al (2015) Skin response to a carcinogen involve sthe xenobiotic receptor pregnane X receptor. Exp Dermatol 24:835–840. https://doi.org/10.1111/exd.12766
    Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587. https://doi.org/10.1074/jbc.M010173200
    Handschin C, Meyer UA (2003) Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 55:649–673. https://doi.org/10.1124/pr.55.4.2.649
    Healan-Greenberg C, Waring J, Kempf D, Blomme EA, Tirona RG, Kim RB (2008) A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos 36:500–507. https://doi.org/10.1124/dmd.107.019547
    Hoffart E, Ghebreghiorghis L, Nussler AK et al (2012) Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor. Br J Pharmacol 165:1595–1608. https://doi.org/10.1111/j.1476-5381.2011.01665.x
    Huang H, Wang H, Sinz M et al (2007) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268. https://doi.org/10.1038/sj.onc.1209788
    Hustert E, Zibat A, Presecan-Siedel E et al (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454–1459
    Iversen PW, Eastwood BJ, Sittampalam GS, Cox KL (2006) A comparison of assay performance measures in screening assays: signal window, Z′ factor, and assay variability ratio. J Biomol Screen 11:247–252. https://doi.org/10.1177/1087057105285610
    Jeske J, Windshugel B, Thasler WE, Schwab M, Burk O (2017) Human pregnane X receptor is activated by dibenzazepine carbamate-based inhibitors of constitutive androstane receptor. Arch Toxicol. https://doi.org/10.1007/s00204-017-1948-3
    Kandel BA, Thomas M, Winter S et al (2016) Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARα in primary human hepatocytes. Biochim Biophys Acta 1859:1218–1227. https://doi.org/10.1016/j.bbagrm.2016.03.007
    Krausova L, Stejskalova L, Wang H et al (2011) Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem Pharmacol 1:1771–1780. https://doi.org/10.1016/j.bcp.2011.08.023
    Lee SM, Schelcher C, Demmel M et al (2013) Isolation of human hepatocytes by a two-step collagenase perfusion procedure. J Vis Exp. https://doi.org/10.3791/50615
    Lemaire G, Benod C, Nahoum V et al (2007) Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to “in vivo” biological activity. Mol Pharmacol 72:572–581. https://doi.org/10.1124/mol.106.033415
    Lim Y-P, Ma C-Y, Liu C-L et al (2012) Sesamin: a naturally occurring lignan inhibits CYP3A4 by antagonizing the pregnane X receptor activation. Evid Based Complement Alternat Med 2012:242810. https://doi.org/10.1155/2012/242810
    Lin W, Wang YM, Chai SC et al (2017) SPA70 is a potent antagonist of human pregnane X receptor. Nat Commun 8:741. https://doi.org/10.1038/s41467-017-00780-5
    Liu C-L, Lim Y-P, Hu M-L (2012) Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs 10:242–257. https://doi.org/10.3390/md10010242
    Moore TW, Mayne CG, Katzenellenbogen JA (2010) Minireview: not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 24:683–695. https://doi.org/10.1210/me.2009-0362
    Piedade R, Traub S, Bitter A et al (2015) Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor. Antimicrob Agents Chemother 59:96–104. https://doi.org/10.1128/AAC.04140-14
    Pissios P, Tzameli I, Kushner P, Moore DD (2000) Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Mol Cell 6:245–253 pii]
    Ratajewski M, Grzelak I, Wiśniewska K et al (2015) Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett 232:193–202. https://doi.org/10.1016/j.toxlet.2014.10.009
    Riedmaier S, Klein K, Hofmann U et al (2010) UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 87:65–73. https://doi.org/10.1038/clpt.2009.181
    Sinz M, Kim S, Zhu Z et al (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375–388
    Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584–590. https://doi.org/10.1038/87912
    Tabb MM, Kholodovych V, Grün F et al (2004) Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ Health Perspect 112:163–169
    Takeshita A, Taguchi M, Koibuchi N, Ozawa Y (2002) Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 277:32453–32458. https://doi.org/10.1074/jbc.M111245200
    Thasler WE, Weiss TS, Schillhorn K et al (2003) Charitable state-controlled foundation human tissue and cell research: ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 4:49–56. https://doi.org/10.1023/A:1026392429112
    Tice CM, Zheng Y-J (2016) Non-canonical modulators of nuclear receptors. Bioorg Med Chem Lett 26:2157–2164. https://doi.org/10.1016/j.bmcl.2016.07.067
    Tolson AH, Wang H (2010) Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62:1238–1249. https://doi.org/10.1016/j.addr.2010.08.006
    van Geel RM, Beijnen JH, Schellens JH (2012) Concise drug review: pazopanib and axitinib. Oncologist 17:1081–1089. https://doi.org/10.1634/theoncologist.2012-0055
    Venkatesh M, Wang H, Cayer J et al (2011) In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol 80:124–135. https://doi.org/10.1124/mol.111.071787
    Wang H, Faucette S, Sueyoshi T et al (2003) A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278:14146–14152. https://doi.org/10.1074/jbc.M212482200
    Wang H, Huang H, Li H et al (2007) Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res 13:2488–2495. https://doi.org/10.1158/1078-0432.CCR-06-1592
    Wang H, Li H, Moore LB et al (2008) The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol 22:838–857. https://doi.org/10.1210/me.2007-0218
    Wang H, Venkatesh M, Li H et al (2011) Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest 121:3220–3232. https://doi.org/10.1172/JCI41514
    Wang YM, Ong SS, Chai SC, Chen T (2012) Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol 8:803–817. https://doi.org/10.1517/17425255.2012.685237
    Zhang J, Chung TDY, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67–73. https://doi.org/10.1177/108705719900400206
    Zhou C, Poulton E-J, Grün F et al (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220–229. https://doi.org/10.1124/mol.106.029264
    Zhu Z, Kim S, Chen T et al (2004) Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 9:533–540. https://doi.org/10.1177/1087057104264902
    Zhuo W, Hu L, Lv J et al (2014) Role of pregnane X receptor in chemotherapeutic treatment. Cancer Chemother Pharmacol 74:217–227. https://doi.org/10.1007/s00280-014-2494-9
    Zollinger M, Waldmeier F, Hartmann S et al (2006) Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos 34:765–774. https://doi.org/10.1124/dmd.105.007732

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2020